A small tablet, but a big effect, New pharmaceutical auxiliaries release active ingredients more quickly
Smaller and smaller tablets make it easier to take medication. With Kollidon® CL-F and Kollidon® CL-SF, BASF is now launching two new tablet disintegrants that are particularly suitable for the manufacture of very small tablets. The new disintegrants ensure that the tablets disintegrate quickly and thereby increase the bioavailability of the active pharmaceutical ingredients, which can be released even more rapidly. This is achieved by means of the special swelling properties of the popcorn polymers Kollidon® CL-F and Kollidon® CL-SF. Both products are characterized by a small particle size. “In this way, our customers can achieve uniform distribution, even in small tablets”, explains Dr. Hubertus Folttmann, who is responsible for the global marketing of pharmaceutical auxiliaries at BASF.
The consistency of tablets also plays an important role for patients who take medication. “Particularly in the case of fast-disintegrating tablets, it is essential that all the ingredients feel good in the mouth”, reports Folttmann. “Here, Kollidon® CL-SF, especially, contributes to a pleasant feeling in the mouth.”
The new, highly functional tablet disintegrants are additions to the existing Kollidon® CL range. “Thus, in each case, we offer our customers the choice of specific disintegrants for their particular application”, says Folttmann.
The new products Kollidon® CL-F and Kollidon® CL-SF will be presented to the pharmaceutical industry for the first time at the conference of the “Controlled Release Society” in Vienna, Austria
(July 22-26, 2006).
Note for editors:
A press photograph can be downloaded from the Internet at www.basf.de/pressphotos, keyword “Fine Chemicals”.
BASF produces and markets a broad range of active ingredients and excipients, as well as exclusive synthesis services for the pharmaceutical industry. These products are made using the latest technologies, to the highest quality standards and in compliance with cGMP guidelines.
Further information can be found at: www.pharma-solutions.basf.com
- Contact Information
- Claudia Schneider
- Media Contact
- Contact via E-mail
This news content was configured by WebWire editorial staff. Linking is permitted.
News Release Distribution and Press Release Distribution Services Provided by WebWire.